Litcius/Paper detail

KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam

Vincenzo Di Pilato, Noemi Aiezza, Valentina Viaggi, Alberto Antonelli, Luigi Principe, Tommaso Giani, Francesco Luzzaro, Gian María Rossolini

2020Antimicrobial Agents and Chemotherapy30 citationsDOIOpen Access PDF

Abstract

This study reports on the characterization of a Klebsiella pneumoniae clinical isolate showing high-level resistance to ceftazidime-avibactam associated with the production of KPC-53, a KPC-3 variant exhibiting a Leu167Glu168 duplication in the Ω-loop and a loss of carbapenemase activity. Whole-genome sequencing (WGS) revealed the presence of two copies of bla KPC-53 , located on a pKpQIL-like plasmid and on a plasmid prophage of the Siphoviridae family, respectively.

Topics & Concepts

Ceftazidime/avibactamKlebsiella pneumoniaeProphagePlasmidCeftazidimeBiologyAvibactamGene duplicationGenotypingGeneticsMicrobiologyGenotypeDNAGeneBacteriophageBacteriaPseudomonas aeruginosaEscherichia coliAntibiotic Resistance in BacteriaGenomics and Phylogenetic StudiesPlant Pathogenic Bacteria Studies
KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam | Litcius